Phenytoin

Generic Name: Phenytoin

Brand Names: Dilantin, Phenytek

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₂N_₂O_₂

CAS Number: 57-41-0

Unique Ingredient Identifier: 6158TKW0C5

Background: Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants. Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina prote...

Indication: Phenytoin is indicated to treat grand mal seizures, complex partial seizures, and to prevent and treat seizures during or following neurosurgery. Injectable phenytoin and Fosphenytoin, which is the phosphate ester prodrug formulation of phenytoin, are indicated to treat tonic-clonic status epilepticus, and for the prevention and treatment of seizures occurri...

Associated Conditions: Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Grand Mal Status Epilepticus, Jacksonian epilepsy, Partial-Onset Seizures, Petit Mal Epilepsy, Seizure Disorder, Post Traumatic, Seizures, Status; Epilepticus, Tonic-clonic, Temporal Lobe Epilepsy (TLE), Convulsive disorders

Associated Therapies: -

Clinical Trials

Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study

Phase 4

Completed

Conditions: Cognitive Measures
Driving Simulator Performance

Interventions: Drug: Phenytoin
Drug: Placebo oral capsule

First Posted Date: 2007-12-28

Last Posted Date: 2021-07-01

Lead Sponsor: University of Iowa

Target Recruit Count: 20

Registration Number: NCT00581893

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures

Phase 4

Completed

Conditions: Tonic-clonic Seizure

Interventions: Drug: Keppra
Drug: Fosphenytoin
Drug: Dilantin

First Posted Date: 2007-08-02

Last Posted Date: 2013-12-12

Lead Sponsor: Emory University

Target Recruit Count: 158

Registration Number: NCT00510783

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

Study of Efficacy of Phenytoin in Therapy of Children With Bronchial Asthma

Phase 4

Completed

Conditions: Bronchial Asthma

First Posted Date: 2006-08-18

Last Posted Date: 2009-02-19

Lead Sponsor: Centre of Chinese Medicine, Georgia

Target Recruit Count: 50

Registration Number: NCT00366067

Locations: 🇬🇪
"Rea" Rehabilitation Centre, Tbilisi, Georgia

Pilot Trial of Neural Correlates of Response to Treatment of PTSD-Associated Impulsive Aggression

Not Applicable

Conditions: Impulsive Aggression
Posttraumatic Stress Disorder

First Posted Date: 2006-06-06

Last Posted Date: 2006-06-06

Lead Sponsor: Michael E. DeBakey VA Medical Center

Target Recruit Count: 12

Registration Number: NCT00333931

Locations: 🇺🇸
Veterans Affairs Medical Center, Houston, Texas, United States

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: Total Body Irradiation (TBI)
Drug: Granulocyte colony-stimulating factor (G-CSF)
Drug: Phenytoin
Drug: Methotrexate

First Posted Date: 2005-10-27

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 147

Registration Number: NCT00245037

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Prediction of Drug Interactions With CYP2C9 Substrates

Not Applicable

Completed

Conditions: Healthy Volunteers

First Posted Date: 2005-09-27

Last Posted Date: 2008-10-29

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 16

Registration Number: NCT00226538

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Determinants of Warfarin Metabolism

Not Applicable

Conditions: Healthy

Interventions: Drug: Warfarin
Drug: Phenytoin

First Posted Date: 2005-09-13

Last Posted Date: 2018-06-12

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 600

Registration Number: NCT00162474

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Phenytoin as an Augmentation for SSRI Failures

Phase 4

Completed

Conditions: Depression

First Posted Date: 2005-09-07

Last Posted Date: 2009-11-25

Lead Sponsor: Beersheva Mental Health Center

Target Recruit Count: 40

Registration Number: NCT00146237

Locations: 🇮🇱
Sarah Herzog Memorial Hospital, Jerusalem, Israel
🇮🇱
Beersheva Mental Health Center, Beersheva, Israel

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Phase 2

Terminated

Conditions: Sickle Cell Anemia
Hemoglobinopathy
Thalassemia

First Posted Date: 2002-06-28

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 15

Registration Number: NCT00040469

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures

Phase 3

Completed

Conditions: Post-Traumatic Seizure Disorder
Head Injuries

First Posted Date: 2000-02-25

Last Posted Date: 2005-06-24

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 385

Registration Number: NCT00004817

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy